Owing to the deficiency of a protein called dystrophin, the muscles of an individual are weakened, resulting in progressive muscle degeneration, which is called Duchenne muscular dystrophy. This medical disorder can be attributed to one of four conditions called dystrophinopathies.

WILMINGTON, Del. , July 16, 2024 /PRNewswire/ -- The projected advancement of the global Duchenne muscular dystrophy market is expected to traverse an impressive development path during the forecasted period. The ecosystem is likely to encompass a CAGR of 11.7% through 2034.

Owing to the surge in different demand drivers, the competitive landscape will navigate through different prospective chances, enabling the industry to reach USD 7.4 billion by 2034. The sector was valued at USD 2.2 billion in 2023.

The progress of the industry is attributed to the rising prevalence of Duchenne muscular dystrophy. With the growing number of patients affected due to such a genetic disorder, the demand for treatment for such disorders is surging. This factor drives the industry size.

Statistics related to this rising number are indicative of the growing market for Duchenne muscular dystrophy. North America and Europe combined forecasted that about 6 of 100,000 people are likely to be affected with the disease.

Request a PDF Sample of this Report Now!
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=28145 

With the proliferation of awareness campaigns, people have started to become more alert regarding the muscular disorder. This results in a rising number of patients approaching for medical help, which elevates prospects for the said sector.

Key players in the Duchenne muscular dystrophy industry are aiming to invest more in research and development projects. This will help such players to find new therapies and treatments to treat patients. Such developments will lead to the augmentation of the industry.

New technologies like exon skipping technology are emerging in the field, which benefits patients. Such a catalyst accelerates the growth of the ecosystem and generates more prospects for existing players.

Different tests, pertaining to the diseases, are gaining momentum in the sector, which is expected to predict the progression of the disease more accurately. As a result, more patients will likely benefit from accurate diagnosis.

The growing investments in the research and development sector are expected to fuel new inventions. Drug development and repurposing are expected to gain momentum in the forecasted era, attributing to the proliferation of the global Duchenne muscular dystrophy market.

Government initiatives to consolidate the healthcare infrastructure to cater to the diverse requirements of patients an indicative of a better future for the said sector. With the medical field being bolstered, better treatments in terms of efficiency and efficacy can be provided to patients.

Duchenne Muscular Dystrophy Market Report Scope:

Key Findings from the Market Report

• The competitive landscape of Duchenne muscular dystrophy is classified based on different parameters. Based on the type of treatment, steroid therapy is expected to gain traction. As steroids can strengthen muscles, the therapy is expected to be used widely.
• Molecular-based therapies leverage the generation of dystrophin, which includes the use of exon-skipping therapies. This helps the patient recover partially, albeit not fully, from the disease.
• Physical therapy is expected to gain attention as such treatments can be provided without frequent assistance from a medical expert.
• Based on the end-user segment, hospitals are expected to govern a large share of the industry. Due to cutting-edge facilities, patients tend to rely more on hospitals.

Regional Profile

• With the growing healthcare infrastructure in developing countries of Asia-Pacific, more prospects will be created for the Duchenne muscular dystrophy market.
• With spurring research activities in Europe, better medical treatments can be provided to patients.
• The development of the healthcare sector and cutting-edge technology will allow key players in the region to expand in the industry.

Unlock Growth Potential in Your Industry! Download PDF Brochure -https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=28145

Competitive Landscape

The vast competitive landscape of Duchenne muscular dystrophy is explored by key players using product launches, partnerships, acquisitions, and many more.

• Pfizer Inc. is a key player that produces different drugs like etomidate, Ampicillin Sodium, argatroban injection, and so on.
• F. Hoffmann-La Roche Ltd. offers many solutions, including CellCept, Copegus, Avastin, and so on.
• Mylan N.V. operates in different areas like gastro and transplant care, oncology, infectious diseases, and dermatology.

Key Players

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Fresenius Kabi AG
• Hikma Pharmaceuticals plc
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Bristol Myers Squibb Company
• GSK plc
• Bayer AG
• Sun Pharmaceutical Industries Ltd.
• Boehringer Ingelheim
• Sanofi
• Sarepta Therapeutics Inc.

Key Developments in the Duchenne Muscular Dystrophy Market

• In December 2023, Pfizer Inc. acquired Seagen. The strategic move has leveraged a consolidated position in the industry for the firm.
• In December 2023, F. Hoffmann-La Roche Ltd. acquired LumiraDx's Point of Care technology.

Download our PDF brochure for comprehensive insights on this report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=28145

Market Segmentation

Treatment Type

• Molecular-based Therapies
• Steroid Therapy
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Physical Therapy
• Others (Surgery, etc.)

End User

• Hospitals
• Specialty Clinics
• Others (Research Institutes, etc.)

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Buy this Premium Research Report:
https://www.transparencymarketresearch.com/checkout.php?rep_id=28145&ltype=S 

More Trending Reports by Transparency Market Research –

• Diabetes Devices Market - The global diabetes devices market is projected to advance at a CAGR of 6.0% from 2022 to 2031.
• Vaccines Market - The global vaccines market is projected to expand at a CAGR of 4.2% during the forecast period from 2023 to 2031.
• Laser Capture Microdissection Market: Market for Laser Capture Microdissection is expected to grow at a CAGR of 10.7% from 2024 to 2034 and reach US$ 739.6 Mn by the end of 2034.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com   
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn | Twitter | Blog | YouTube

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/duchenne-muscular-dystrophy-market-on-track-to-surpass-us-7-4-billion-by-2034-at-cagr-of-11-7--analysis-by-transparency-market-research-inc-302198199.html

SOURCE Transparency Market Research